BofA downgrades Amrize stock on growth concerns, cuts price target to $40
BofA Securities downgraded Amrize Ltd (NYSE:AMRZ) to Underperform, cutting its price target to $40 from $50. The stock is near its 52-week low, down 20% YTD. BofA reduced 2027-28 EBITDA estimates by 3%, citing growth concerns, U.S. cement price stability, and Canada macro risks. Amrize's Q2 earnings missed estimates, though revenue beat forecasts. Other analysts also downgraded the stock due to earnings misses and management changes.
How this was made
The 30-second read
Why it matters
The combined analyst actions and earnings miss suggest heightened volatility and a likely price dip.
Market read
Analyst downgrades following a Q2 earnings miss could trigger short‑term selling pressure on AMRZ.
What to watch
Potential upside from M&A optionality and any unexpected demand rebound in roofing markets.
Background
Amrize reported mixed Q2 results, beating revenue but missing earnings, prompting multiple analyst downgrades.
Ticker impact
BofA downgraded Amrize to Underperform and cut its price target to $40, citing growth concerns and weaker earnings outlook.
Potential short‑term decline, likely 3‑5% pullback.
Analyst downgrade with a target below current price typically triggers sell‑side activity, especially after a Q2 earnings miss.
Market effects
The downgrade may weigh on the construction materials sector, highlighting sensitivity to cement price stability and macro conditions.
North American construction stocks could see modest pressure.
Limited to investors tracking US mid‑cap industrials.
Counterpoint
If the company can stabilize cement margins and benefit from upcoming infrastructure spending, the downgrade may be overblown.
Key entities
- AnalystBofA Securities
Downgraded Amrize to Underperform and cut price target.
- AnalystRBC Capital
Also downgraded Amrize, lowering its target to $48.
- AnalystJPMorgan
Downgraded Amrize to Neutral due to management turnover.
